Introduction
============

Moyamoya vasculopathy (MMV) is a cerebrovascular disorder of largely unknown etiology characterized by progressive stenosis or occlusion of the supraclinoid internal carotid arteries and their proximal branches \[[@b1-jos-2018-01550],[@b2-jos-2018-01550]\]. Patients may present with transient ischemic attacks (TIAs) and ischemic stroke but also with headache, movement disorders, and seizures \[[@b1-jos-2018-01550],[@b3-jos-2018-01550]\]. MMV can also lead to cognitive impairment \[[@b4-jos-2018-01550]\]. Cognitive functions may not only be affected by overt or silent brain infarcts or hemorrhages but also by chronic hypoperfusion, as cognitive impairment has been diagnosed in adults with MMV without stroke \[[@b5-jos-2018-01550]\]. Early age of onset and longer disease duration have been associated with the occurrence of cognitive impairment \[[@b6-jos-2018-01550]\]. Many patients with MMV undergo surgical revascularization to improve cerebral blood flow (CBF) and prevent future ischemic stroke \[[@b2-jos-2018-01550]\], but prospective studies on the effect of surgical treatment on cognition are lacking. A previously published descriptive review has provided an overview on cognition in moyamoya disease (MMD) suggesting that the impact of MMV on cognition is more pronounced in children than in adults \[[@b7-jos-2018-01550]\]. In the present study we systematically collected and meta-analyzed available quantitative information on the presence, severity and nature of cognitive impairment in children and adults with MMV and its determinants, in particular cerebral perfusion. Furthermore, we aimed to determine the effect of surgical intervention on cognition.

Methods
=======

For the conduction of this systematic review we followed the meta-analysis of observational studies in epidemiology (MOOSE) guidelines \[[@b8-jos-2018-01550]\].

Search strategy and selection criteria
--------------------------------------

We searched Ovid Medline and Embase for publications of studies describing cognitive function in patients with MMV published between January 1, 1969 (the year the disorder was given its name) and October 4, 2016 (see online [Supplementary for Syntax](#SD8-jos-2018-01550){ref-type="supplementary-material"}). No limits were set for languages; native speakers translated papers that were written in other languages than English, German, or French. Titles and abstracts were scanned and papers were included on the basis of full text by two authors independently (A.K. and C.J.M.K.); disagreement was resolved by consensus. Additional studies were included from the reference lists of included studies. We included studies reporting cognitive or intellectual functioning in children and adults that allowed analysis of quantitative data on group level (i.e., intelligence quotient \[IQ\] scores) of at least five patients. If authors reported neuropsychological assessment without providing raw neuropsychological data, we contacted them for additional data. In case of (suspected) overlap between study cohorts, we included the study with the largest sample size with information on the proportion of patients with impaired cognition. In case individual patient data were provided, we excluded patients without quantitative cognitive data.

Data extraction
---------------

Three authors (A.K. all papers; C.J.M.K. and E.B. half of the studies each) independently extracted data from selected papers. Disagreements were solved by consensus. Of the authors from 13 publications who were approached for additional data, one provided baseline characteristics and scores of neuropsychological tests \[[@b9-jos-2018-01550]\], five could not provide additional information, and seven authors did not respond. The risk of bias was evaluated by one author (A.K.) using the Newcastle-Ottawa scale adapted for cross-sectional studies (see online [Supplementary for the Risk Assessment](#SD9-jos-2018-01550){ref-type="supplementary-material"}) \[[@b10-jos-2018-01550]\].

We collected the following study characteristics: study design; midyear of study; in- and exclusion criteria; number of patients with MMD or moyamoya syndrome (MMS, known associated disease) \[[@b1-jos-2018-01550]\]; mean age and duration of symptoms (at time of diagnosis; presentation; neuropsychological assessment, operation, inclusion or not specified); proportion of females; ethnicity (Asian, Caucasian, Hispanic, African, and Afro-American, according to the definition provided by the authors, or---if not provided---by country of publication); site of clinical stroke or TIA (uni- or bilateral); application of diagnostic criteria for MMV \[[@b1-jos-2018-01550]\]; site of vasculopathy; and site of (silent) stroke on imaging; and results of CBF and cerebrovascular reserve (CVR) studies. We divided presenting symptoms into four categories depending on the information provided by the authors: (1) ischemic stroke only; (2) TIA(s) only; (3) hemorrhage; or (4) other symptoms. We collected information on the level of education and occupation. In studies that provided longitudinal assessment of cognitive functioning, data were also collected for the second time-point, including the type of revascularization in surgically treated patients.

From the neuropsychological assessments we extracted the following data: mean full-scale intelligent quotient (FSIQ), developmental quotient (DQ) (pooled with FSIQ as IQ); verbal intelligent quotient (VIQ); performance intelligent quotient (PIQ); raw or standardized z-scores of cognitive tests; and the proportion of patients with cognitive impairment overall and per cognitive domain ([Supplementary Table 1](#SD1-jos-2018-01550){ref-type="supplementary-material"} summarizes the specific neuropsychological tests applied by each study). For studies that did not provide the proportion of patients with cognitive impairment, we calculated the proportion based on published normative data if possible. For DQ (a ratio calculated by dividing the mental developmental age with the chronological age) we appointed to have the same norm sample as (FS)IQ, unless otherwise specified \[[@b11-jos-2018-01550]\]. Cognitive test results derived from neuropsychological evaluation were grouped into six predefined cognitive domains according to standard neuropsychological practice specified in Lezak: intelligence, memory, processing speed, attention and executive functions, visual perception and construction, and language ([Supplementary Table 2](#SD2-jos-2018-01550){ref-type="supplementary-material"}) \[[@b12-jos-2018-01550]\]. In studies that provided results of multiple cognitive tests investigating the same domain, we determined the mean score and, if possible, calculated the mean z-scores and standard deviations (SDs) for the domain. A z-score is a standardized score which entails the number of SDs that an individual test result differs from the mean score in healthy controls, thereby indicating the relative location of a measurement within its distribution \[[@b13-jos-2018-01550]\].

Data analysis
-------------

To assess the presence of cognitive impairment, we determined the median proportion of patients with cognitive impairment. Cognitive impairment was defined according to the authors' criteria, or as a cognitive score (overall, or on a specific domain, or on at least two tests) deviating more than 1.5 SD from the population mean, or IQ \<85. To assess the severity of the impairment, we calculated the median cognitive scores of the various cognitive tests. To determine whether mean age, ethnicity, sex, mean duration of symptoms, and presenting symptoms were determinants of cognitive impairment, we performed linear regression analysis weighted by the inverse standard error of the proportion of patients with impaired cognition. Due to lack of data, this could not be performed for other patients' characteristics. We qualitatively determined the reported association between frontal CBF and CVR and cognitive impairment as reported by the authors.

In studies that provided longitudinal assessment of cognitive function, we determined whether cognitive functions improved, deteriorated or remained stable over time. For intelligence, we used a cut-off point of more than 10 points differences of IQ scores at follow-up. For cognitive domains, change over time was categorized according to the criteria provided by the authors.

Results
=======

After screening 299 studies (66 studies were screened on full text), we included 17 studies reporting cognitive function in a total of 434 patients ([Figure 1](#f1-jos-2018-01550){ref-type="fig"}). Eleven studies reported on 281 children and six studies on 153 adults. [Tables 1](#t1-jos-2018-01550){ref-type="table"} and [2](#t2-jos-2018-01550){ref-type="table"} and [Supplementary Tables 3](#SD3-jos-2018-01550){ref-type="supplementary-material"} and [4](#SD4-jos-2018-01550){ref-type="supplementary-material"} summccs and neuropsychological test results \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b9-jos-2018-01550],[@b14-jos-2018-01550]-[@b27-jos-2018-01550]\]. Four studies reported on cerebral hemodynamic measures in relation to cognitive functions \[[@b4-jos-2018-01550],[@b9-jos-2018-01550],[@b17-jos-2018-01550],[@b21-jos-2018-01550]\]. Nine studies reported longitudinal assessment of cognitive function over time, eight of which provided data after surgical treatment in children; one after conservative treatment in adults ([Table 2](#t2-jos-2018-01550){ref-type="table"} and [Supplementary Table 5](#SD5-jos-2018-01550){ref-type="supplementary-material"}) \[[@b4-jos-2018-01550],[@b15-jos-2018-01550]-[@b20-jos-2018-01550],[@b22-jos-2018-01550],[@b23-jos-2018-01550]\]. Study quality varied between three and six out of seven: three studies had a total score of 3 \[[@b4-jos-2018-01550],[@b21-jos-2018-01550],[@b22-jos-2018-01550]\]; five studies a score of 4 \[[@b16-jos-2018-01550],[@b18-jos-2018-01550]-[@b20-jos-2018-01550],[@b23-jos-2018-01550]\]; five studies a score of 5 \[[@b6-jos-2018-01550],[@b9-jos-2018-01550],[@b17-jos-2018-01550],[@b25-jos-2018-01550],[@b27-jos-2018-01550]\]; and four studies a score of 6.14,15,24,26 The most important reasons for studies having a risk of bias were: sample size \<30 patients (65%) and no information on whether patients were included consecutively (87%) ([Supplementary Table 6](#SD6-jos-2018-01550){ref-type="supplementary-material"}).

Children
--------

In the 11 studies reporting on children, median age of the study cohorts was 9.4 years (range, 5.9 to 13.9); the median percentage females 55% (range, 33% to 75%; 10 studies, 268 patients). All studies except one \[[@b14-jos-2018-01550]\] described Asian cohorts of which nine were Japanese. Two studies described the criteria they used for the diagnosis of MMV: confirmation by angiographic evidence of moyamoya collaterals and stenosis in one study \[[@b14-jos-2018-01550]\] and according to Sato et al. \[[@b20-jos-2018-01550]\] in the other. One paper reported the inclusion of patients with MMS (n=20) \[[@b14-jos-2018-01550]\]. Presenting symptoms were reported in 10 studies (216 children). The median proportion of children presenting with ischemic stroke was 31% (range, 0% to 60%; nine studies, 166 patients), and with TIA only 69% (range, 40% to 100%; nine studies, 166 patients) \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b14-jos-2018-01550],[@b16-jos-2018-01550]-[@b18-jos-2018-01550],[@b20-jos-2018-01550]-[@b22-jos-2018-01550]\]. Presentation with hemorrhage was rare (one patient in 166 children in nine studies). One study (50 patients) did not report symptoms that could be classified according to our predefined categories \[[@b19-jos-2018-01550]\].

The median duration of symptoms was 27.0 months (range, 12.6 to 57.8). We found no information on school performance or the presence of depression among the pediatric studies.

### Cognitive impairment

The median proportion of children with cognitive impairment overall was 30% (range, 13% to 67%; seven studies, 133 patients) ([Figure 2](#f2-jos-2018-01550){ref-type="fig"}) with a median IQ score of 101 (range, 71 to 107) \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b17-jos-2018-01550]-[@b21-jos-2018-01550]\]. In the included 11 studies, the median IQ score was 98 (range, 71 to 107) \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b14-jos-2018-01550]-[@b22-jos-2018-01550]\], median VIQ score was 97 (range, 77 to 108; seven studies, 170 children) \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b14-jos-2018-01550],[@b15-jos-2018-01550],[@b18-jos-2018-01550],[@b20-jos-2018-01550],[@b22-jos-2018-01550]\], and median PIQ score was 100 (range, 89 to 109; six studies, 163 children) \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b14-jos-2018-01550],[@b15-jos-2018-01550],[@b18-jos-2018-01550],[@b22-jos-2018-01550]\]. Three studies reported on specific cognitive domains \[[@b6-jos-2018-01550],[@b14-jos-2018-01550],[@b15-jos-2018-01550]\]. Memory was affected in 15% of patients (one study, 13 patients) \[[@b6-jos-2018-01550]\]. Eight percent of the patients had impairment in processing speed and attention and executive functions, and 18% in the visual perception and construction domain (one study, 13 patients) \[[@b6-jos-2018-01550]\]. The median z-score for memory was --0.39 (range, --0.85 to 0.45; three studies, 108 children) \[[@b6-jos-2018-01550],[@b14-jos-2018-01550],[@b15-jos-2018-01550]\] and for processing speed --0.43 (range, --0.86 to 0.00; two studies, 43 children) \[[@b6-jos-2018-01550],[@b14-jos-2018-01550]\]. One study (13 patients) assessed additional domains with mean z-scores of 0.50 for attention and executive function; and --0.53 for visual perception and construction \[[@b6-jos-2018-01550]\].

We found no association between mean age (B=--0.014; 95% confidence interval \[CI\], --0.112 to 0.083; *P*=0.723); type of presenting symptom (for infarction \[B=--0.002; 95% CI, --0.017 to 0.013; P=0.672\] and for TIA \[B=--0.002; 95% CI, --0.013 to 0.017; P=0.672); mean duration of symptoms (B=0.000; 95% CI, --0.016 to 0.016; P=0.945); and proportion of females (B=--0.005; 95% CI, --0.025 to 0.014; P=0.508), and the proportion of patients with cognitive impairment ([Supplementary Table 7](#SD7-jos-2018-01550){ref-type="supplementary-material"}) \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b18-jos-2018-01550],[@b20-jos-2018-01550],[@b21-jos-2018-01550]\].

### Cerebral blood flow

Three studies investigated the relation between CBF (xenon-enhanced computed tomography \[CT\] \[[@b4-jos-2018-01550]\] or single photon emission CT \[SPECT\]) \[[@b17-jos-2018-01550]\] and IQ scores \[[@b21-jos-2018-01550]\]. In one study, patients with a lower IQ showed a tendency for a more marked depression of mean CBF than those with a normal IQ (quantitative analysis not provided) \[[@b4-jos-2018-01550]\]. Another study reported a marked depression of CBF (qualitatively determined) in the frontal lobes in seven out of nine patients, all having normal IQ scores \[[@b17-jos-2018-01550]\]. The third study reported no relation between abnormal patterns of CBF and IQ \[[@b21-jos-2018-01550]\].

### Longitudinal results

Eight studies (199 patients) evaluated the effect of revascularization surgery on cognitive performances after a median follow-up period of 35.3 months (range, 6.5 to 113) \[[@b4-jos-2018-01550],[@b15-jos-2018-01550]-[@b20-jos-2018-01550],[@b22-jos-2018-01550]\]. All eight studies reported IQ and one also assessed memory. Indirect revascularization was performed in 90.5% of the patients, direct in 0.5% and combined in 9%. The median proportion of children with impaired intelligence pre-operatively was 33% (range, 13% to 67%; four studies, 88 children) and at followup after revascularization 35% (range, 13% to 58%; four studies, 81 children) \[[@b17-jos-2018-01550]-[@b20-jos-2018-01550]\]. In the other four studies proportions of children with impaired IQs were not reported post-operatively.

Median scores at follow-up were: for IQ 97 (range, 68 to 108; six studies, 161 children) with a pre-operative median IQ score in these studies of 101 (range, 71 to 107; 170 children); for VIQ 97 (range, 82 to 106; four studies, 107 children) with a pre-operative median VIQ score of 101 (range, 77 to 108; 107 children); and for PIQ 102 (range, 100 to 109; three studies, 100 children) with a pre-operative median PIQ score of 100 (range, 97 to 109; 100 children).

Based on available individual patient data, improvement in IQ (≥10 points) was observed in a median proportion of 27% of patients (range, 5.5% to 53%; five studies, 91 children) \[[@b4-jos-2018-01550],[@b17-jos-2018-01550],[@b19-jos-2018-01550],[@b20-jos-2018-01550],[@b22-jos-2018-01550]\], no change in 56% (range, 40% to 89%; four studies, 76 children) and deterioration in 15% (range, 5.5% to 25%; four studies, 76 children). Improvement in VIQ was seen in 20% (range, 13% to 29%; three studies, 37 children) \[[@b4-jos-2018-01550],[@b20-jos-2018-01550],[@b22-jos-2018-01550]\], no change in 65% (57% and 73%; two studies, 22 children) and deterioration in 13.5% (13% and 14%; two studies, 22 children). PIQ scores improved in 63.5% (60% and 67%; two studies, 30 patients), remained stable in 20% (one study, 15 patients) and deteriorated in 13% (one study, 15 patients) \[[@b4-jos-2018-01550],[@b22-jos-2018-01550]\]. Memory function improved after surgery (pre-operative z-score 0.45; after surgery 0.77) \[[@b15-jos-2018-01550]\]. One study in which 18 out of the 38 patients were operated on (five combined, 13 indirect) reported no improvement of IQ after revascularization (no quantitative data available) \[[@b16-jos-2018-01550]\].

Adults
------

In the six studies reporting on adults, median age was 40.1 years (range, 36.6 to 43.7) and the median percentage of females 63% (range, 46% to 74%) \[[@b9-jos-2018-01550],[@b23-jos-2018-01550]-[@b27-jos-2018-01550]\]. Of a total of 153 patients, 87 were Asian (57%), 56 Caucasian (37%), and 10 had another ethnicity (7%). The median proportion of adults presenting with ischemic stroke was 27% (range, 0% to 72%; five studies, 117 patients), TIA only 17% (range, 0% to 54%; five studies, 117 patients), hemorrhage 3% (range, 0% to 100%; five studies, 117 patients), and 19% (range, 0% to 57%; five studies, 117 patients) had other symptoms \[[@b9-jos-2018-01550],[@b23-jos-2018-01550],[@b25-jos-2018-01550]-[@b27-jos-2018-01550]\]. The median duration of symptoms at assessment or inclusion was 18.6 months (1.2 and 36.1 months; two studies).

### Cognitive impairment

The median proportion of patients with cognitive impairment was 31% (range, 0% to 69%; five studies, 127 patients) \[[@b9-jos-2018-01550],[@b23-jos-2018-01550]-[@b25-jos-2018-01550],[@b27-jos-2018-01550]\]. In the four studies investigating cognition by means of a neuropsychological test battery, the median proportion with impaired cognition on one or more of the reported domains was 42.5% (range, 30% to 69%) \[[@b9-jos-2018-01550],[@b24-jos-2018-01550],[@b25-jos-2018-01550],[@b27-jos-2018-01550]\]. The median IQ score was 95 (range, 94 to 99; three studies, 88 patients) \[[@b24-jos-2018-01550],[@b25-jos-2018-01550],[@b27-jos-2018-01550]\]; median VIQ score was 94 and median PIQ score 93 (two studies, 59 patients).

Four studies (101 patients) reported on specific cognitive domains \[[@b9-jos-2018-01550],[@b24-jos-2018-01550],[@b25-jos-2018-01550],[@b27-jos-2018-01550]\]. The median proportion of patients with impaired memory was 37% (range, 7% to 54%), impaired processing speed 28% (range, 21% to 39%), impaired attention and executive functions 37% (range, 19% to 54%), impaired visual perception and construction 23% (range, 22% to 29%), and impaired language 35% (range, 20% to 40%) \[[@b9-jos-2018-01550],[@b24-jos-2018-01550],[@b25-jos-2018-01550],[@b27-jos-2018-01550]\]. The median z-scores (three studies, 78 patients) were: for memory --0.4 (range, --1.1 to --0.2), for processing speed --0.9 (range, --1.7 to --0.8), for attention and executive function --0.9 (range, --0.95 to --0.4), for visual perception and construction --0.4 (range, --0.5 to --0.2), and for language --0.6 (range, --0.8 to --0.15). One study of patients with an intraventricular hemorrhage (IVH) showed a mean score within the normal range (27.4±1.2 \[range, 26 to 29\]) on the Montreal Cognitive Assessment (MoCA) \[[@b23-jos-2018-01550]\].

We found no association between mean age (B=--0.044; 95% CI, --0.184 to 0.096; *P*=0.387) or proportion of females (B=0.011; 95% CI, --0.031 to 0.053; *P*=0.460) and cognitive impairment ([Supplementary Table 7](#SD7-jos-2018-01550){ref-type="supplementary-material"}). Analysis of the association of type of presenting symptom and cognitive impairment was not possible, because of lack of data categorized according to our predefined classification.

The mean duration of education was 12.1±3.1 years (three studies, 91 patients) \[[@b24-jos-2018-01550]-[@b26-jos-2018-01550]\]. In a series of 26 patients from one study, nine finished college or a higher-level education, five primary school or less, and 12 middle school \[[@b23-jos-2018-01550]\]. Another study of 36 patients reported that 25 participated in a full-time job, five were unemployed and five were homemakers; one patient had retired \[[@b24-jos-2018-01550]\].

### Cerebral blood flow studies

One study reported a correlation of the apparent diffusion coefficient (ADC) in normal appearing frontal white matter on diffusion weighted imaging with CVR on perfusion magnetic resonance imaging and executive functions (Spearman coefficient, --0.46; *P*=0.01) \[[@b9-jos-2018-01550]\]. Elevation of ADC was significantly correlated with executive dysfunction (area under the curve for cognitive impairment, 0.85; 95% CI, 0.59 to 1.16; *P*=0.032).

### Longitudinal results

In the study assessing cognitive impairment in patients with solely IVH, all patients had normal MoCA scores at baseline (mean MoCA score 27.4±1.2 \[range, 26 to 39\]) and mild cognitive impairments after a mean follow-up of 24 months (mean MoCA score 18.7±1.3 \[range, 16 to 21\]) without treatment \[[@b23-jos-2018-01550]\].

Discussion
==========

Our systematic review shows that around 30% of children and of adults have cognitive impairment. When assessed on a group level, median IQ scores are within the normal range in both children and adults. Information on specific domains of cognitive function is limited, with relatively modest impairments in memory and processing speed observed in children, and modest to large impairments across various cognitive domains in adults.

Since there was not a large discrepancy between VIQ and PIQ, total IQ scores provide a reliable insight in cognitive functioning in children. Longitudinal results in children showed that IQ scores on a group level remained within normal limits over time. In adults, longitudinal studies of neuropsychological assessments other than with a screening test have not been performed.

In a previous review, the authors concluded that cognition is affected more frequently in children than in adults, reporting intelligence to be impaired in children, and executive functions in adults \[[@b7-jos-2018-01550]\]. However, our systematic review and meta-analysis show that in adults the proportion of patients with impairment of cognitive function is as large as in children. In comparison with this aforementioned review, we included five additional studies on children \[[@b6-jos-2018-01550],[@b14-jos-2018-01550],[@b15-jos-2018-01550],[@b21-jos-2018-01550],[@b22-jos-2018-01550]\] and four recent studies on adults \[[@b9-jos-2018-01550],[@b23-jos-2018-01550],[@b26-jos-2018-01550],[@b27-jos-2018-01550]\]; and excluded studies without quantitative data. Although the highest median percentage of impaired function was found in the domain attention and executive functions, we found similar proportions of patients with impairment for the other cognitive domains. In children, other domains than intelligence were investigated in only three studies. Patients with a normal intelligence may show selective cognitive impairment in other cognitive domains. Therefore, extensive neuropsychological evaluation is of great importance, also in children who generally show a diffusely impaired cognitive profile in case of cognitive deterioration because their brain is still developing.

It remains uncertain if the neurocognitive profile of patients with MMS differs from that in patients with MMD, since the presence of associated diseases was reported in only one study, which did not demonstrate a difference between these groups \[[@b14-jos-2018-01550]\].

We did not find an association between the predefined determinants and the proportion of patients with cognitive impairment, probably due to the limited data available. Some of the included studies suggested that age at onset \[[@b4-jos-2018-01550],[@b6-jos-2018-01550],[@b22-jos-2018-01550]\] and longer duration of disease were \[[@b6-jos-2018-01550]\] associated with cognitive dysfunction, however we could not confirm these associations in our metaanalysis. Previous studies were small including 13 to 20 patients and observed associations may have been due to chance. Information on the determinants of cognitive impairment and its course is scarce. The relation between cerebral perfusion and cognition in children remains unclear, whereas in adults, a single study suggested a relation between diminished perfusion in the frontal matter and executive dysfunction. Several studies have suggested that (frontal) hypoperfusion, white matter disease and infarction are associated with cognitive disturbances \[[@b28-jos-2018-01550]-[@b31-jos-2018-01550]\]. It remains unclear whether MMV directly affects cognition by chronic hypoperfusion, or that cognitive impairment is mainly the result of stroke. The observed impaired cognition in patients without stroke supports the hypothesis that chronic hypoperfusion is a contributing factor to cognitive impairment in patients with MMV \[[@b5-jos-2018-01550],[@b6-jos-2018-01550]\]. One study reported that executive dysfunction was associated with stroke and white matter lesions and not with CVR; however, patients with higher baseline CBF had better cognitive functioning \[[@b32-jos-2018-01550]\]. Improvement in intelligence and cerebral perfusion in children has been observed after revascularization surgery \[[@b4-jos-2018-01550],[@b17-jos-2018-01550]\], and for this reason frontal revascularization procedures are performed more often \[[@b2-jos-2018-01550],[@b17-jos-2018-01550],[@b33-jos-2018-01550]\]. Whether prevention of cognitive decline should be an indication for revascularization surgery in patients with MMV remains unclear. Although our review shows that a fair number of patients improved or remained stable after revascularization, the quantity of the included data is too limited to draw final conclusions.

Although we were able to collect a reasonable amount of data on cognitive function in patients with MMV, the review was limited by the relatively low number of patients described in the individual studies. Information bias could not be avoided, given the large heterogeneity of the reported cognitive tests. Since little information on patients' characteristics was available, results could be influenced by selection bias and we could not control for confounding factors like the presence of silent infarction on imaging. Finally, we were not able to perform meta-analysis of the relation between CBF and cognition and of the effect of revascularization due to the low number and heterogeneity of studies. Our review also has strengths. We were able to quantify cognitive impairments in MMV. In addition, we were able to eliminate the risk of selection bias due to language since we did not include language restrictions. Despite these methodological shortcomings, our results give valuable insight in the presence, severity and nature of cognitive functions in MMV before and after revascularization, since we quantified cognitive impairments in MMV.

Conclusions
===========

Large prospective studies with a standardized neuropsychological test battery are needed to determine the severity of cognitive impairment and the domains affected. Information on school level and performance, and on work status is also of importance, since it reflects function rather than deficits \[[@b34-jos-2018-01550]\]. It remains to be established whether cognitive outcome can be improved by revascularization surgery.
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###### 

Basic characteristics of studies and neuropsychological results in children and adults with moyamoya vasculopathy

  Study                                                                                                 No.                                                     Age (yr)                                                               Presenting symptoms (%)       Duration (mo)                                                          Cognitive impairment overall (%)   FSIQ impaired (%)   VIQ impaired (%)   PIQ impaired (%)   Memory impaired (%)   Procspeed impaired (%)                                 Att/EF impaired (%)                                        Visper/const impaired (%)   Language impaired (%)
  ----------------------------------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------- ---------------------------------------------------------------------- ---------------------------------- ------------------- ------------------ ------------------ --------------------- ------------------------------------------------------ ---------------------------------------------------------- --------------------------- -----------------------
  Hsu et al. (2014) \[[@b6-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^           13                                                      13.9±6.3 (6--17)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^       TIA 100                       17±15.9 (1--48)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^        39                                 0                   17                 0                  15                    8                                                      8                                                          18                          \-
  Williams et al. (2012) \[[@b14-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^     30                                                      10.1±4^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^                 Infarction 50                 35.0±49 (2--204)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^       \-                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  Lee et al. (2011) \[[@b15-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^          65                                                      9.1 (4--17)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^            \-                            \-                                                                     \-                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  Imaizumi et al. (1999) \[[@b16-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^     38                                                      6.5±3.3 (1--13)^[‡](#tfn3-jos-2018-01550){ref-type="table-fn"}^        Infarction 26                 16.2±16.1 (160)^[‡](#tfn3-jos-2018-01550){ref-type="table-fn"}^        \-                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 63                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Other 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Ohtaki et al. (1998) \[[@b17-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^       8^[§](#tfn4-jos-2018-01550){ref-type="table-fn"}^       7.1±2.0 (5--11)^[‖](#tfn5-jos-2018-01550){ref-type="table-fn"}^        Minor completed stroke 12.5   18.9±19.7 (2--60)^[‖](#tfn5-jos-2018-01550){ref-type="table-fn"}^      13                                 13                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  Hemorrhage 12.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  TIA 75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Matsushima et al. (1997) \[[@b18-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^   20                                                      9.6±3.4^[‖](#tfn5-jos-2018-01550){ref-type="table-fn"}^                Infarction 30                 \-                                                                     15                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Matsushima et al. (1991) \[[@b19-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^   50^[¶](#tfn6-jos-2018-01550){ref-type="table-fn"}^      9.4±4.3 (2--21)^[‖](#tfn5-jos-2018-01550){ref-type="table-fn"}^        Movement disorder 80          55.8±50.7 (0--188)^[‖](#tfn5-jos-2018-01550){ref-type="table-fn"}^     50                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  Seizures 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Headache 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Involuntary movements 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Sato et al. (1990) \[[@b20-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^         12^[\*\*](#tfn7-jos-2018-01550){ref-type="table-fn"}^   5.9±2.3 (1--10)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^        Ischemia 50                   12.6±10.6 (1--31)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^      67                                 \-                  57                 56                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 50%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Tagawa et al. (1989) \[[@b21-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^       10^[††](#tfn8-jos-2018-01550){ref-type="table-fn"}^     10.2±3.2 (6−15)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^        Infarction 10                 57.8±50.5 (13−155)^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^     30                                 30                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 90                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Ibayashi et al. (1985) \[[@b22-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^     15                                                      9.2±3.3 (5−16)^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^        Completed stroke 53           48.3±44.3 (19--136)^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^   \-                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Ishii et al. (1984) \[[@b4-jos-2018-01550]\]^[\*](#tfn1-jos-2018-01550){ref-type="table-fn"}^         20                                                      9.9±3.1 (5--16)^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^       Completed stroke 60           \-                                                                     22                                 22                  21                 26                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Lei et al. (2017) \[[@b26-jos-2018-01550]\]^[§§](#tfn10-jos-2018-01550){ref-type="table-fn"}^         26                                                      40.2±9.4^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^              Minor stroke 27               \-                                                                     \-                                 \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  TIA 54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Headache 19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Kazumata et al. (2015) \[[@b27-jos-2018-01550]\]^[§§](#tfn10-jos-2018-01550){ref-type="table-fn"}^    23                                                      40.9±9.5 (21--58)^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^     TIA 43                        \-                                                                     30                                 8                   4                  17                 35                    33                                                     30                                                         22                          39
  Asymptomatic 57                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Su et al. (2013) \[[@b23-jos-2018-01550]\]^[§§](#tfn10-jos-2018-01550){ref-type="table-fn"}^          26                                                      43.7±8.6 (26--59)^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^     Hemorrhage 100                1.2^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^                    0                                  \-                  \-                 \-                 \-                    \-                                                     \-                                                         \-                          \-
  Calviere et al. (2012) \[[@b9-jos-2018-01550]\]^[§§](#tfn10-jos-2018-01550){ref-type="table-fn"}^     13                                                      36.6±12.9^[‡‡](#tfn9-jos-2018-01550){ref-type="table-fn"}^             Ischemic stroke 62            36.1^[‖‖](#tfn11-jos-2018-01550){ref-type="table-fn"}^                 54                                 \-                  \-                 \-                 54                    23                                                     54                                                         23                          31
  Hemorrhage 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Other 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Festa et al. (2010) \[[@b25-jos-2018-01550]\]^[§§](#tfn10-jos-2018-01550){ref-type="table-fn"}^       29                                                      39.9±11.2 (20--65)^[‖‖](#tfn11-jos-2018-01550){ref-type="table-fn"}^   Ischemic stroke 72            \-                                                                     69                                 \-                  \-                 \-                 39                    21^[¶¶](#tfn12-jos-2018-01550){ref-type="table-fn"}^   19^[\*\*\*](#tfn13-jos-2018-01550){ref-type="table-fn"}^   29                          20
  TIA 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Hemorrhage 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Other 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Karzmark et al. (2008) \[[@b24-jos-2018-01550]\]^[§§](#tfn10-jos-2018-01550){ref-type="table-fn"}^    36                                                      36.6±9.9^[†](#tfn2-jos-2018-01550){ref-type="table-fn"}^               \-                            \-                                                                     31                                 19                  25                 25                 7                     39                                                     43                                                         23                          40

Values are presented as mean±standard deviation (range) or mean±standard deviation.

FSIQ, full-scale intelligent quotient; VIQ, verbal intelligence quotient; PIQ, performal intelligence quotient; Procspeed, processing speed; Att, attention; EF, executive function; Visper/const, visual perception/construction; TIA, transient ischemic attack.

Studies reporting results in children;

At neuropsychological assessment;

At diagnosis;

Excluding 2 patients (1 scaled out, 1 not investigated);

At operation;

Study included 65 patients with preoperative data in 50 patients;

Study included 13 patients from which 12 had preoperative data;

Study included 21 patients from which 10 had preoperative data;

Not specified;

Studies reporting results in adults;

At presentation;

n=19;

n=16.

###### 

Longitudinal neuropsychological test performances

  Study                                                                                                  FU period (mo)                                                         Impairment overall (A/B) (%)^[\*](#tfn14-jos-2018-01550){ref-type="table-fn"}^   Improved (%)   Stable (%)   Deteriorated (%)
  ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------- ------------ ------------------
  Lee et al. (2011) \[[@b15-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^          19^[‡](#tfn16-jos-2018-01550){ref-type="table-fn"}^ (5-46)             \-                                                                               \-             \-           \-
  Imaizumi et al. (1999) \[[@b16-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^     \>120^[§](#tfn17-jos-2018-01550){ref-type="table-fn"}^                 \-                                                                               \-             \-           \-
  Ohtaki et al. (1998) \[[@b17-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^       85.2±32.59^[‖](#tfn18-jos-2018-01550){ref-type="table-fn"}^ (23-110)   13/13                                                                            12             63           25
  Matsushima et al. (1997) \[[@b18-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^   113^[‡](#tfn16-jos-2018-01550){ref-type="table-fn"}^                   15/20                                                                            \-             \-           \-
  Matsushima et al. (1991) \[[@b19-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^   26.2±14.7^[‡](#tfn16-jos-2018-01550){ref-type="table-fn"}^ (7-58)      50/49                                                                            27             49           24
  Sato et al. (1990) \[[@b20-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^         44.4±26.3^[¶](#tfn19-jos-2018-01550){ref-type="table-fn"}^ (4-99)      67/58                                                                            PIQ 11         PIQ 78       PIQ 11
  VIQ 29                                                                                                 VIQ 57                                                                 VIQ 14                                                                                                       
  DQ 0                                                                                                   DQ 100                                                                 DQ 0                                                                                                         
  Ibayashi et al. (1985) \[[@b22-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^     6.5±4.9^[‡](#tfn16-jos-2018-01550){ref-type="table-fn"}^ (1-17)        \-                                                                               FSIQ 47        \-           \-
  VIQ 20                                                                                                                                                                                                                                                                                     
  PIQ 60                                                                                                                                                                                                                                                                                     
  Ishii et al. (1984) \[[@b4-jos-2018-01550]\] ^[†](#tfn15-jos-2018-01550){ref-type="table-fn"}^         6--68^[‡](#tfn16-jos-2018-01550){ref-type="table-fn"}^                 22/-                                                                             FSIQ 53        FSIQ 40      FSIQ 6
  VIQ 13                                                                                                 VIQ 73                                                                 VIQ 13                                                                                                       
  PIQ 67                                                                                                 PIQ 20                                                                 PIQ 13                                                                                                       
  Su et al. (2013) \[[@b23-jos-2018-01550]\]^[\*\*](#tfn20-jos-2018-01550){ref-type="table-fn"}^         24^[‖](#tfn18-jos-2018-01550){ref-type="table-fn"}^                    0/100                                                                            0              0            100

Values are presented as median (range), mean±standard deviation (range), or range.

FU, follow-up; PIQ, performal intelligence quotient; VIQ, verbal intelligence quotient; DQ, developmental quotient; FSIQ, full-scale intelligent quotient.

A/B, prior neuropsychological test result/longitudinal neuropsychological test result;

Studies reporting results in children;

FU period defined as time of operation to NPA;

FU period defined as time from onset of disease to neurospychological assessment;

FU period defined as time of NPA to NPA;

FU period unspecified;

Studies reporting results in adults.
